CoChat

Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells

Mota Reyes, Carmen, Teller, Steffen, Muckenhuber, Alexander, Konukiewitz, Björn, Safak, Okan, Weichert, Wilko, Friess, Helmut, Ceyhan, Güralp O., Demir, Ihsan Ekin · 2020 · Clinical Cancer Research

Published version of a preprint

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Purpose: Neoadjuvant therapy (neoTx) has dramatically improved the prognosis of patients with locally advanced and borderline resectable pancreatic ductal adenocarcinoma, yet its mechanisms of action on tumor cells and the tumor microenvironment are still unknown. Here, we aimed to characterize the multiple facets of neoTx-induced alterations in the pancreatic cancer microenvironment. Experimental Design: We performed the currently most comprehensive histopathologic analysis of desmoplasia, angiogenesis, neural invasion, and immune cell infiltration at the tumor–host interface of pancreatic cancer after neoTx (n = 37) versus after primary resection (n = 37) through quantitative IHC and double immunofluorescence using automated and software-based quantification algorithms. Results: We demonstrate that, independently of the applied pretreatment, neoadjuvant regimes are able to reverse the immunosuppressive behavior of malignant cells on pancreatic cancer microenvironment. Here, neoTx-driven selective depletion of regulatory T cells and myeloid-derived suppressor cells was associated with enrichment of antitumor immune cells in the peritumoral niche, decreased stromal activation, and less neural invasion. Importantly, the degree of this antitumor immune remodeling correlates to the degree of histopathologic response to neoTx. Survival analysis revealed that the tumor proliferation rate together with the activation of the stroma and the intratumoral infiltration with CD4+ T cells and natural killer cells constitute as independent prognostic factors for neoadjuvantly treated pancreatic cancer. Conclusions: NeoTx is not only cytotoxic but has pleiotropic, beneficial effects on all cellular and noncellular components of pancreatic cancer. Combinational approaches including immunotherapy may unleash long-term and more effective antitumor responses and improve prognosis of pancreatic cancer.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-1864

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Cited by

See all 85

Metadata

Authors
Mota Reyes, C., Teller, S., Muckenhuber, A., Konukiewitz, B., Safak, O., Weichert, W., Friess, H., Ceyhan, G. O., & Demir, I. E.
Affiliations
  • 1Department of Surgery, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • TUM Klinikum (DE)
Venue
Clinical Cancer Research
Published
2020-01-01
Volume
26
Issue
1
Pages
220-231
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2978682544
Cited by
80
References
35
Citations by year
2026: 6 · 2025: 10 · 2024: 12 · 2023: 14 · 2022: 18 · 2021: 14 · 2020: 6
FWCI
3.96
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Funders
German Cancer Aid (70112897)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Keywords
neoadjuvant therapy, pancreatic ductal adenocarcinoma, tumor microenvironment, immune cell depletion, regulatory T cells, myeloid-derived suppressor cells, antitumor immunity, desmoplasia, tumor angiogenesis, perineural invasion, CD4+ T cells, natural killer cells, prognostic factors, immunotherapy
MeSH terms
Myeloid-Derived Suppressor Cells, Adenocarcinoma, Aged, Aged, 80 and over, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Biomarkers, Tumor, CD4-Positive T-Lymphocytes, Survival Rate, CD8-Positive T-Lymphocytes, Neoadjuvant Therapy, Carcinoma, Pancreatic Ductal, T-Lymphocytes, Regulatory, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-1864
The paper
Mota Reyes, C., Teller, S., Muckenhuber, A., Konukiewitz, B., Safak, O., Weichert, W., Friess, H., Ceyhan, G. O., & Demir, I. E. (2020). Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-1864

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.